Description

Clinical trials have shown remarkable decreases in body weight, often exceeding results from existing GLP‑1 agonists. It works by reducing appetite, slowing gastric emptying, and increasing energy expenditure through glucagon receptor activity.

2. Improved Glucose Control
By activating GLP‑1 and GIP receptors, Retatrutide may enhance insulin secretion and glucose uptake while lowering fasting blood glucose and HbA1c levels—making it a strong investigational candidate for type 2 diabetes management.

3. Enhanced Metabolic Efficiency
The triple‑agonism appears to promote fat oxidation and reduce visceral fat, supporting better metabolic health and potentially improving lipid profiles.

4. Cardiovascular and Inflammatory Benefits
Some research suggests GLP‑1/GIP/glucagon receptor modulation may have cardioprotective and anti‑inflammatory effects, though this remains under early investigation.

5. Potential for Non‑Alcoholic Fatty Liver Disease (NAFLD)
Due to its impact on fat metabolism and hepatic lipid clearance, Retatrutide is being studied for potential roles in reducing liver fat content and improving markers of hepatic function.